Skip to content
AusGrant
Federal Open GRANTS-GOV-362196

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award

Defense Health Agency Contracting Activity - DHACA (DOD) · Competitive grant · Science & Technology

At a glance

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award is a federal competitive grant from Defense Health Agency Contracting Activity - DHACA for the science & technology sector. Funding is up to $2K. Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility". The application deadline is September 30, 2026. Apply via the official listing at www.grants.gov.

Amount
Up to $2K
Deadline
Sep 30, 2026
Type
Competitive
Status
Open

About this program

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.

Who can apply

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

How to apply

Apply through Grants.gov using funding opportunity number HT942526ALSRPTDA. Register your organization (SAM.gov + Grants.gov) before the deadline, then submit the application package listed in the official notice.

Apply at official source